INNOVATE (US:VATE)2026-03-26 20:17Financial Performance - INNOVATE Corp. reported consolidated revenue of $382.7 million for Q4 2025, a 61.7% increase from $236.6 million in Q4 2024[2] - The company's net loss attributable to common stockholders decreased to $7.8 million in Q4 2025, compared to a loss of $16.9 million in Q4 2024, marking a 53.8% improvement[12] - Total Adjusted EBITDA for Q4 2025 was $24.5 million, a 63.3% increase from $15.0 million in Q4 2024, driven primarily by the Infrastructure segment[12] - For Q4 2025, revenue was $382.7 million, a 61.5% increase from $236.6 million in Q4 2024; full-year revenue reached $1,246.0 million, up 12.6% from $1,107.1 million in 2024[33] - Gross profit for Q4 2025 was $58.9 million, compared to $46.4 million in Q4 2024, while full-year gross profit was $199.7 million, down from $208.8 million in 2024[33] - The net loss attributable to INNOVATE Corp. for Q4 2025 was $7.4 million, an improvement from a net loss of $16.6 million in Q4 2024; for the full year, the net loss was $60.6 million compared to $34.6 million in 2024[33] - Adjusted EBITDA for the three months ended December 31, 2025, was $24.5 million, compared to $15.0 million for the same period in 2024, reflecting a growth of 63.3%[37] - INNOVATE Corp. reported a net income of $29.5 million for the year ended December 31, 2025, compared to a net loss of $60.6 million in the same period of 2024[39] - Adjusted EBITDA for 2025 was $67.2 million, a decrease from $71.3 million in 2024, reflecting a decline of approximately 5.8%[39] Revenue Segments - The Infrastructure segment generated $373.9 million in revenue for Q4 2025, up 65.7% from $225.7 million in the prior year quarter, contributing significantly to overall growth[8] - The Spectrum segment reported a revenue decline to $5.7 million in Q4 2025 from $6.8 million in the prior year quarter, impacted by a softened advertising market[8] Cash and Assets - As of December 31, 2025, INNOVATE had cash and cash equivalents of $112.1 million, up from $48.8 million as of December 31, 2024[17] - Total current assets rose to $451.5 million in 2025, up from $390.9 million in 2024, which is an increase of 15.5%[35] - Total assets increased to $950.1 million in 2025, up from $891.1 million in 2024, representing a growth of 6.2%[35] - Current liabilities surged to $1,034.1 million in 2025, compared to $483.0 million in 2024, indicating a significant increase of 114.4%[35] - Total liabilities reached $1,165.4 million in 2025, up from $1,034.8 million in 2024, which is an increase of 12.6%[35] Operational Insights - INNOVATE's operating expenses for Q4 2025 were $45.0 million, slightly up from $44.8 million in Q4 2024, with selling, general and administrative expenses at $40.6 million[33] - The company reported a loss from operations before income taxes of $9.3 million in Q4 2025, an improvement from a loss of $14.9 million in Q4 2024[33] - DBM Global's gross margin was 14.7% in Q4 2025, a decrease of approximately 350 basis points year-over-year, indicating challenges in maintaining profitability[8] Future Outlook - INNOVATE is positioned for growth in 2026, supported by favorable contracts and ongoing trials with a major mobile wireless carrier[3] - The company plans to continue expanding its market presence and capitalize on potential growth opportunities in its strategic segments[26] - Forward-looking statements indicate expectations for future growth and performance in new projects and technologies, with a focus on advertising revenue growth and commercial opportunities in datacasting[26] - INNOVATE Corp. plans to focus on market expansion and new product development to drive future growth[39] - The company is actively pursuing acquisition opportunities to enhance its portfolio and market presence[39] Product Development - MediBeacon received FDA approval for the next generation MediBeacon TGFR System, enhancing the company's product offerings in Life Sciences[8] - R2 secured a minimum purchase agreement for 600 systems over three years in China, reflecting growing international demand[8] Interest and Expenses - Interest expense for the three months ended December 31, 2025, totaled $24.0 million, compared to $19.6 million in the same period of 2024, representing an increase of 22.4%[37] - The company incurred interest expenses totaling $89.0 million in 2025, up from $74.5 million in 2024, indicating a year-over-year increase of 19.8%[39] - Depreciation and amortization expenses were $17.5 million in 2025, slightly lower than $17.6 million in 2024[39] Losses and Deficits - The accumulated deficit increased to $(582.5) million in 2025 from $(521.9) million in 2024, indicating a deterioration of 11.6%[35] - The company reported a net loss in the Life Sciences segment of $3.5 million for Q4 2025, an improvement from a loss of $5.4 million in Q4 2024[37] - The company’s life sciences segment reported a net loss of $23.5 million in 2025, compared to a loss of $20.0 million in 2024, indicating a worsening performance[39] - The company reported a non-controlling interest loss of $3.4 million in 2025, compared to a loss of $5.1 million in 2024, showing a reduction of approximately 33.3%[39] - Realignment and exit costs amounted to $5.1 million in 2025, consistent with the $5.2 million reported in 2024[39]